# Phase 1 Urinary Bladder cancer trials recruiting: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 1 for Urinary Bladder cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Urinary Bladder cancer trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/urinary-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 19, 2026 | NCT07881666 | Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure | Hopec Pharma | Phase 1 | Recruiting | Urinary Bladder Neoplasms | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881666) |
| October 1, 2026 | NCT07853053 | DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 | Not yet recruiting | Bladder Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853053) |
| August 25, 2026 | NCT07783815 | A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With... | Xiangya Hospital of Central South University | Phase 1 | Not yet recruiting | Bladder Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783815) |
| June 24, 2026 | NCT07664397 | Imaging Study of \[89Zr\]DFO-YS5 for Cancer Detection | Sponsor not shown (see the record) | Phase 1 | Recruiting | Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664397) |
| June 22, 2026 | NCT07660055 | Study of \[177Lu\]Lu-DWJ155 and \[68Ga\]Ga-DWJ155 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660055) |
| April 29, 2026 | NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial | Sponsor not shown (see the record) | Phase 1 | Recruiting | Bladder Tumors, Bladder Tumor, Urothelial Carcinoma (UC), Urothelial Carcinoma Bladder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555769) |
| March 25, 2026 | NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma | Beijing Biotech | Phase 1 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492628) |
| January 22, 2026 | NCT07359235 | Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) | Tongji Hospital | Phase 1 | Recruiting | Bladder Cancer (BC) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359235) |
| January 13, 2026 | NCT07337525 | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Pilatus Biosciences Inc | Phase 1 | Recruiting | Advanced Malignant Solid Tumor, Solid Tumor Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07337525) |
| December 11, 2025 | NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | IDEAYA Biosciences | Phase 1 | Recruiting | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277413) |
| December 3, 2025 | NCT07260162 | Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) | Institut Cancerologie de l'Ouest | Phase 1 | Not yet recruiting | Bladder Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260162) |
| October 16, 2025 | NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | ImmunityBio, Inc. | Phase 1 | Not yet recruiting | Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217496) |
| October 15, 2025 | NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell... | EvolveImmune United, Inc | Phase 1 | Recruiting | Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217171) |
| October 3, 2025 | NCT07206225 | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Pfizer | Phase 1 | Recruiting | Non-muscle Invasive Bladder Cancer | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206225) |
| August 24, 2025 | NCT07140315 | DK222 Study at Hopkins | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | Recruiting | Non-Small Cell Lung Cancer, Urothelial Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140315) |
| August 13, 2025 | NCT07119996 | Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07119996) |
| July 29, 2025 | NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090499) |
| July 8, 2025 | NCT07053735 | An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer | Peking University First Hospital | Phase 1 | Not yet recruiting | Bladder (Urothelial, Transitional Cell) Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053735) |
| May 9, 2025 | NCT06963346 | Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Recruiting | Bladder Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963346) |
| April 4, 2025 | NCT06910657 | IDOV-Immune for Advanced Solid Tumors | ViroMissile, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06910657) |
| January 16, 2025 | NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Clasp Therapeutics, Inc. | Phase 1 | Recruiting | Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06778863) |
| October 16, 2024 | NCT06644755 | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | Daiichi Sankyo | Phase 1 | Recruiting | Solid Tumors, Sarcoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06644755) |
| September 19, 2024 | NCT06586255 | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Urothelial Carcinoma Bladder, Bladder Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06586255) |
| July 31, 2024 | NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | Washington University School of Medicine | Phase 1 | Recruiting | Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06529822) |
| June 18, 2024 | NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Eli Lilly and Company | Phase 1 | Recruiting | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast... | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06465069) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| University of California, Davis | 1 |
| Pilatus Biosciences Inc | 1 |
| IDEAYA Biosciences | 1 |
| Institut Cancerologie de l'Ouest | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| ViroMissile, Inc. | 1 |
| Washington University School of Medicine | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Tongji Hospital | 1 |
| Baylor College of Medicine | 1 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 1 |
| Peking University First Hospital | 1 |
| Hopec Pharma | 1 |
| Xiangya Hospital of Central South University | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| OncoNano Medicine, Inc. | 1 |
| Clasp Therapeutics, Inc. | 1 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 8 |
| South Korea | 6 |
| France | 6 |
| United Kingdom | 6 |
| Australia | 6 |
| Spain | 5 |
| Canada | 3 |
| Israel | 3 |
| Japan | 3 |
| Netherlands | 2 |
| Puerto Rico | 1 |
| Denmark | 1 |
| Germany | 1 |
| Italy | 1 |
| Norway | 1 |
| Switzerland | 1 |
| Taiwan | 1 |
| Belgium | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [B2B direct mail advertising companies in the United States](https://specstream.ai/data/businesses/b2b-direct-mail-advertising-companies/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
